Jaroslaw Cisowski

Dr. Jaroslaw Cisowski


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
TGTomasz Gromowski
Tomasz Gromowski
VLVeronika Lukacs-Kornek
Veronika Lukacs-Kornek
JCJaroslaw Cisowski
Jaroslaw Cisowski
Hepatocellular carcinoma and intrahepatic cholangiocarcinoma are devastating primary liver cancers with increasing prevalence in many parts of the world. Despite intense investigation, many aspects of their biology are still largely obscure. For example, numerous studies have tackled the question of the cell-of-origin of primary liver cancers using different experimental approaches; they have not, however, provided a clear and undisputed answer. Here, we will review the evidence from animal models supporting the role of all major types of liver epithelial cells: hepatocytes, cholangiocytes, and their common progenitor as liver cancer cell-of-origin. Moreover, we will also propose mechanisms that promote liver cancer cell plasticity (dedifferentiation, transdifferentiation, and epithelial-to-mesenchymal transition) which may contribute to misinterpretation of the results and which make the issue of liver cancer cell-of-origin particularly complex.

6 November 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JCJaroslaw Cisowski
Jaroslaw Cisowski
Ahmed Ezat El ZowalatyAhmed Ezat El Zowalaty
Ahmed Ezat El Zowalaty
SSSama I. Sayin
Sama I. Sayin
PCPiotr Czarnota
Piotr Czarnota
TGTomasz Gromowski
Tomasz Gromowski
MBMartin Bergo
Martin Bergo
The MEK–ERK pathway is a key driver of hepatocellular carcinoma (HCC) pathogenesis, and BRAF mutations, particularly BRAF V600E , can contribute to its activation. Although BRAF V600E mutations are rare in human HCC, they do occur, yet their physiologic impact in liver cells, especially when combined with frequent comutations in tumor suppressor genes, remains poorly understood. Moreover, the effect of BRAF inhibitors on HCC progression and metastasis is not well-defined. Therefore, we developed mouse models with hepatocyte-specific BRAF V600E expression and Trp53 or Cdkn2a deletion to assess tumor development, subtypes, and metastatic patterns. We found that BRAF V600E expression caused hepatomegaly, vascular congestion, and ductal reactions, and led to reduced liver function and early mortality. Codeletion of Trp53 or Cdkn2a markedly increased primary liver tumor incidence and enabled sarcomatoid metastasis. While the BRAF inhibitor PLX4720 effectively reduced primary tumors and extended survival, it paradoxically increased sarcomatoid metastases. Mechanistically, PLX4720 and other RAF inhibitors induced TGFβ2 expression which promoted epithelial-to-mesenchymal transition (EMT) and enhanced tumorigenicity. The effects of RAF inhibitors on TGFβ2 expression were validated in BRAF V600E -mutant human melanoma cells. We conclude that BRAF V600E drives diverse primary tumors but only one type of metastasis and that RAF inhibition, while effective against primary tumors, may promote metastasis through TGFβ2-mediated EMT. Although RAF inhibitors remain promising therapies, their unintended role in enhancing metastasis raises concerns that may extend beyond liver cancer to other BRAF V600E -driven malignancies.

21 February 2023 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
TGTomasz Gromowski
Tomasz Gromowski
VLVeronika Lukacs-Kornek
Veronika Lukacs-Kornek
JCJaroslaw Cisowski
Jaroslaw Cisowski

11 March 2026 in Cell Communication and Signaling
Verified
Journal Article
Open access
PCPiotr Czarnota
Piotr Czarnota
TGTomasz Gromowski
Tomasz Gromowski
AGAnna Golda
Anna Golda
DBDanuta Bryzek
Danuta Bryzek
SLSlawomir Lasota
Slawomir Lasota
JCJaroslaw Cisowski
Jaroslaw Cisowski
Liver cancer often arises in the setting of chronic liver disease and remains a major global health challenge with limited effective treatments. Isoprenylcysteine Carboxyl Methyltransferase (ICMT) is an enzyme that catalyzes the methylation of prenylated proteins containing a CAAX motif, such as RAS, a modification thought to be essential for their function. Given its role in oncogenic signaling, ICMT has emerged as a potential therapeutic target in cancer. Notably, ICMT is overexpressed in human hepatocellular carcinoma (HCC), and previous studies have shown that Icmt deletion impairs Braf V600E -driven transformation in murine fibroblasts. In this study, we investigated the role of ICMT in liver cancer using a genetically engineered mouse model with hepatocyte-specific expression of Braf V600E , combined with deletion of Trp53 and Icmt . We assessed the impact of Icmt loss on liver physiology, tumorigenesis, and global transcriptomic and proteomic landscapes. Expression of Braf V600E led to progressive body weight loss, reduced survival, hepatomegaly, vascular congestion, liver fibrosis, and tumor development. These phenotypic changes were associated with widespread alterations in gene and protein expression, particularly affecting pathways related to cell differentiation, coagulation, and metabolism. Strikingly, liver-specific Icmt deletion ameliorated several pathological features, including weight loss, early mortality, fibrosis, and vascular abnormalities. It also partially normalized the transcriptomic and proteomic profiles. However , Icmt deletion did not prevent hepatomegaly or tumor formation. In conclusion, while ICMT deletion mitigates several deleterious effects of Braf V600E -driven liver pathology, it does not block tumorigenesis. These findings suggest that ICMT is not a suitable therapeutic target for liver cancer prevention or treatment, but may have potential as a target to alleviate liver disease-associated symptoms.